Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer.

Abstract

BACKGROUND:

To improve the prognosis of patients with urachal cancer and establish an effective chemotherapeutic regimen for distant metastases.

METHODS:

We conducted a retrospective study to evaluate the efficacy and safety of a modified combination of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) therapy in patients with metastatic urachal cancer.

RESULTS:

Five patients were treated with mFOLFOX6. Their median age was 65 years (range 41-80). The median follow-up time was 42 months (range 18-46). Two of the 5 patients (40%) showed an objective response: 1 achieved a clinically complete response and 1 a partial response. The grade 3/4 toxicity associated with this regimen was primarily neutropenia, but febrile neutropenia was not observed. Oxaliplatin treatment was discontinued because of a grade 2 allergic reaction in 1 patient. Grade 2 peripheral sensory neuropathy caused by oxaliplatin was observed in 2 patients, and the OPTIMOX (stop and go) approach had to be adopted.

CONCLUSIONS:

mFOLFOX6 appears to be effective for the treatment of metastatic urachal cancer.

• Authors: Yutaka Yanagihara, Nozomu Tanji, Noriyoshi Miura, Akitomi Shirato, Kenichi Nishimura, Tetsuya Fukumoto, Koji Azuma, Yuki Miyauchi, Tadahiko Kikugawa, Masayoshi Yokoyama
• Journal: Chemotherapy (Chemotherapy) Vol. 59 Issue 6 Pg. 402-6 ( 2013) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 24969043 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 S. Karger AG, Basel.

Chemical References

• Organoplatinum Compounds
• Oxaliplatin
• Leucovorin
• Fluorouracil

Topics

• Adult
• Aged
• Aged, 80 and over
• Anemia (etiology)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Female
• Fluorouracil (administration & dosage, adverse effects, therapeutic use)
• Follow-Up Studies
• Humans
• Leucovorin (administration & dosage, adverse effects, therapeutic use)
• Lung Neoplasms (drug therapy, secondary)
• Male
• Middle Aged
• Neutropenia (etiology)
• Organoplatinum Compounds (administration & dosage, adverse effects, therapeutic use)
• Oxaliplatin
• Retrospective Studies
• Treatment Outcome
• Urinary Bladder Neoplasms (drug therapy, pathology)